Metamark Appoints Dr. Anjen Chenn to Senior Vice President of Clinical Operations
CAMBRIDGE, Mass., Dec. 1, 2014 /PRNewswire/ -- Metamark today announced that Anjen Chenn, M.D., Ph.D. has been named the company's new senior vice president of clinical operations. Dr. Chenn will oversee operational execution and pathology services, across Metamark's three laboratories in Cambridge, Massachusetts; Collegeville, Pennsylvania; and Augusta, Georgia.
"Anjen brings a wealth of experience in pathology and a passion to lead all aspects of laboratory development," said Metamark CEO Shawn Marcell. "We are excited to have someone with Anjen's clinical background and management experience join our team as ProMark™ commercialization accelerates and we continue to advance our research and development pipeline. With Anjen on the team, Metamark will continue to lead innovation in prostate cancer and aid patients and healthcare professionals in making important decisions about the treatment of their disease."
Dr. Chenn most recently served as the associate professor of pathology at the University of Illinois, Chicago, where his research lab focused on understanding developmental brain disorders and brain cancer. Dr. Chenn's laboratory received funding from NIH (NINDS, NCI), Sontag Foundation for Brain Tumor Research, Searle Scholars Program, March of Dimes, Simons Foundation for Autism Research Initiative, and the V Foundation. He also served as the director of clinical pathology at the University of Illinois Hospital in Chicago, where he established a new program for Personalized Diagnostics, also known as the Laboratory for Innovative Care and Research. Under his leadership, that program launched several efforts to support patient care decisions, including research to identify genetic variations in cancer that predicted responses to specific therapeutic approaches and the development of clinical diagnostic tests from gene expression signatures.
Previously, Dr. Chenn was a faculty member at Northwestern University Feinberg School of Medicine and served as the director of molecular diagnostics at Northwestern Memorial Hospital in Chicago. While there, he was instrumental in increasing the testing volume and diversity within the laboratory and brought on multiple new tests for molecular oncology, genetic testing, and infectious diseases.
Dr. Chenn received his undergraduate degree in biochemical sciences at Harvard University and his M.D. and Ph.D. in neurosciences from Stanford University. He completed his residency in clinical pathology at the Brigham and Women's Hospital in Boston, Massachusetts, and post-doctoral training in the lab of Dr. Christopher Walsh at Beth Israel Deaconess Medical Center in Boston, and was an instructor at Harvard Medical School. Dr. Chenn is board certified in clinical pathology and molecular genetic pathology from the American Board of Pathology. He has been the recipient of multiple awards and honors and continues to serve on multiple department committees and professional societies.
Additional information about Metamark's executive team and its prostate cancer prognostic tests can also be found at www.metamark.us.
About ProMark™
ProMark™ is designed to improve the accuracy of prognosis for men diagnosed with prostate cancer, specifically the approximately 85% of prostate cancer patients with biopsy Gleason grades 3+3 or 3+4 for whom standard-of-care based medical decision making is currently insufficient. The test measures the amount of specific protein biomarkers obtained by needle biopsy from regions of prostate tissue where the biomarkers are altered during tumor formation. These "regions of interest" are rendered as intact, paraffin-embedded tissue sections. Quantitative measurements of the biomarkers are then determined by means of fully automated digital imaging technology. The resulting analysis is completely objective and fully reproducible. A large, blinded, clinical-validation study of ProMark met its primary endpoint, demonstrating that the test can aid in differentiating between aggressive and indolent disease. The research program supporting ProMark has completed four clinical studies altogether comprising over 1,250 patients, with additional prospective studies underway. Metamark is commercializing ProMark through the company's CLIA-certified laboratory in Cambridge, Massachusetts. For more information, visit: www.metamark.us.
About Metamark
Metamark is a privately held biotechnology company founded to develop novel, function-based, prognostic and diagnostic tests aimed at improving cancer care. The company's proprietary genomic and proteomic discovery platforms have yielded significant discoveries in several disease areas, including prostate, bladder, colon, and breast cancers. Through the acquisition of Healthtronics Laboratory Solutions last year, Metamark has become a leading provider of specialty urological pathology testing services throughout the United States. For more information, please visit the company's website at www.metamark.us. Metamark™ and ProMark™ are trademarks of Metamark.
Logo - http://photos.prnewswire.com/prnh/20141201/161454LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/metamark-appoints-dr-anjen-chenn-to-senior-vice-president-of-clinical-operations-300002402.html
SOURCE Metamark
Share this article